[go: up one dir, main page]

NO20065027L - Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet - Google Patents

Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet

Info

Publication number
NO20065027L
NO20065027L NO20065027A NO20065027A NO20065027L NO 20065027 L NO20065027 L NO 20065027L NO 20065027 A NO20065027 A NO 20065027A NO 20065027 A NO20065027 A NO 20065027A NO 20065027 L NO20065027 L NO 20065027L
Authority
NO
Norway
Prior art keywords
cell culture
culture medium
factor viii
polypeptide
biologically active
Prior art date
Application number
NO20065027A
Other languages
English (en)
Other versions
NO325633B1 (no
Inventor
Lars Adamson
Erik Walum
Johan Dixelius
Kristina Lima Lie
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9601855A external-priority patent/SE9601855D0/xx
Publication of NO20065027L publication Critical patent/NO20065027L/no
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO325633B1 publication Critical patent/NO325633B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20065027A 1996-05-14 2006-11-02 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet NO325633B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9601855A SE9601855D0 (sv) 1996-05-14 1996-05-14 Process for producing a protein
US1887496P 1996-05-29 1996-05-29
PCT/SE1997/000783 WO1997043436A1 (en) 1996-05-14 1997-05-13 A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium

Publications (2)

Publication Number Publication Date
NO20065027L true NO20065027L (no) 1999-01-14
NO325633B1 NO325633B1 (no) 2008-06-30

Family

ID=26662616

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19985297A NO325358B1 (no) 1996-05-14 1998-11-13 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant human blodkoaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet.
NO20065027A NO325633B1 (no) 1996-05-14 2006-11-02 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19985297A NO325358B1 (no) 1996-05-14 1998-11-13 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant human blodkoaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet.

Country Status (13)

Country Link
US (1) US5851800A (no)
EP (1) EP0934424B1 (no)
JP (2) JP2000509994A (no)
AT (2) ATE321141T1 (no)
AU (1) AU716245B2 (no)
CA (1) CA2253287C (no)
DE (2) DE69735510T2 (no)
DK (1) DK0934424T3 (no)
ES (2) ES2260524T3 (no)
NO (2) NO325358B1 (no)
NZ (1) NZ332751A (no)
PT (2) PT1318198E (no)
WO (1) WO1997043436A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
CN100553678C (zh) 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
ATE330003T1 (de) * 1999-08-05 2006-07-15 Baxter Ag Rekombinanter stabiler zellklon, seine herstellung und verwendung
WO2001052891A1 (fr) * 2000-01-20 2001-07-26 Nippon Organon K. K. Inhibiteurs d'invasion plasmodiale dans des erythrocytes
CN100591759C (zh) * 2002-07-09 2010-02-24 巴克斯特国际有限公司 用于细胞培养的无动物蛋白质培养基
PL377731A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
PL377603A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Poprawa jakości produktu w hodowlach komórek ssaczych do wytwarzania białka
MXPA05011486A (es) * 2003-04-25 2006-04-18 Immunex Corp Inductores de expresion de proteina recombinante.
US7255288B2 (en) * 2004-03-08 2007-08-14 Wan Shan Chan Aroma therapy for fountain
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
DK2522717T3 (da) * 2006-01-04 2014-04-22 Baxter Int Oligopeptid-frie cellekulturmedier
PT2126106T (pt) 2007-02-23 2017-12-12 Sk Chemicals Co Ltd Proceso para produzir e purificar o fator viii e seus derivados
WO2008135498A2 (en) * 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
CA2742328C (en) 2008-11-07 2019-02-26 Baxter International Inc. Factor viii formulations
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US10138290B2 (en) 2010-10-05 2018-11-27 Novo Nordisk Healthcare Ag Process for protein production
CN104822826B (zh) 2012-10-15 2019-04-30 百时美施贵宝公司 用于蛋白产生的哺乳动物细胞培养过程
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
BR112019009581A2 (pt) 2016-11-10 2019-10-08 Yuhan Corp composição farmacêutica para evitar ou tratar hepatite, fibrose hepática, e cirrose hepática que compreende proteínas de fusão
MX2019012331A (es) 2017-04-21 2020-01-23 Yuhan Corp Metodo para producir proteinas de doble funcion y sus derivados.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149787A (en) * 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
US5279939A (en) * 1986-08-18 1994-01-18 Smithkline Beecham Corporation Protein protease inhibitors from streptomyces
US4891356A (en) * 1987-07-15 1990-01-02 Brigham & Women's Hospital Proteinase inhibitors for treatment of gastrointestinal ulcer disease
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JP2769170B2 (ja) * 1987-12-08 1998-06-25 ザイモジェネティクス，インコーポレイティド 真核細肪中での同時発現
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
DK457788D0 (da) * 1988-08-16 1988-08-16 Nordisk Gentofte Fremgangsmaade til fremstilling af et oensket polypeptid
WO1990002175A1 (en) * 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2076386C (en) * 1990-02-26 2003-04-22 David S. Hogness Identification and expression of insect steroid receptor dna sequence
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
US5661034A (en) * 1991-07-18 1997-08-26 Fuji Yakuhin Kogyo Kabushiki Kaisha Serum-free medium for tissue culture containing tissue inhibitor of metalloproteinases and method for growing cells using the medium
CA2116774C (en) * 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
US5278289A (en) * 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
WO1995005477A1 (en) * 1993-08-12 1995-02-23 University Of Maryland Thermostable alkaline metalloprotease produced by a hyphomonas, and preparation thereof
US5631159A (en) * 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5543396A (en) * 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives

Also Published As

Publication number Publication date
DE69736391T2 (de) 2007-08-16
EP0934424B1 (en) 2006-07-26
JP2009148271A (ja) 2009-07-09
NZ332751A (en) 2000-06-23
NO325633B1 (no) 2008-06-30
PT1318198E (pt) 2006-08-31
ATE334223T1 (de) 2006-08-15
ES2270460T3 (es) 2007-04-01
US5851800A (en) 1998-12-22
ES2260524T3 (es) 2006-11-01
NO325358B1 (no) 2008-04-07
CA2253287A1 (en) 1997-11-20
NO985297D0 (no) 1998-11-13
DE69735510D1 (de) 2006-05-11
CA2253287C (en) 2008-02-19
DK0934424T3 (da) 2006-11-20
NO985297L (no) 1999-01-14
EP0934424A1 (en) 1999-08-11
ATE321141T1 (de) 2006-04-15
JP4896999B2 (ja) 2012-03-14
DE69736391D1 (de) 2006-09-07
PT934424E (pt) 2006-12-29
JP2000509994A (ja) 2000-08-08
AU2919797A (en) 1997-12-05
AU716245B2 (en) 2000-02-24
WO1997043436A1 (en) 1997-11-20
DE69735510T2 (de) 2006-08-24

Similar Documents

Publication Publication Date Title
NO20065027L (no) Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet
CN101563100B (zh) 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标
Fields The history of leeching and hirudin
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ATE92107T1 (de) N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
US4197291A (en) Hydrolytic enzyme material
EP1107768A4 (en) STABLE HYPOXY INDUCIBLE FACTOR-1 ALPHA AND METHOD OF USE
ES2136599T3 (es) Tratamiento de las heridas utilizando peptidos biologicamente activos.
US4329430A (en) Enzyme mixture
US4307081A (en) Enzyme mixture
ES2060942T3 (es) Terapia genetica utilizando celulas estromicas.
DK0832186T3 (da) Erstatningsterapi til dental caries
Limova et al. Treatment of pyoderma gangrenosutn with cultured keratinocyte autografts
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
US4226854A (en) Debridement of devitalized tissue with hydrolytic enzyme product
HUP9901188A2 (hu) Új, meghatározott enzimkeverékek sejtkinyeréshez és sebkezeléshez
Glyantsev et al. Crab collagenase in wound debridement
EP1539225B1 (en) Apparatus and methods for use in enzymatic escharotomy in burn induced compartment syndrome
ATE390937T1 (de) Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
JP3009741B2 (ja) 骨組織の局所的形成のためのプラスミノーゲンアクティベーターの使用
AU2007266775B2 (en) Chymotrypsin from Lucilia sericata larvae and its use for the treatment of wounds
JPH06509057A (ja) 促進された創傷治癒
CA1077837A (en) Hydrolytic enzyme material

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees